Cite
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
MLA
Stone, John H., et al. “New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from a Randomized Controlled Trial and Extension.” Rheumatology, vol. 61, no. 7, July 2022, pp. 2915–22. EBSCOhost, https://doi.org/10.1093/rheumatology/keab780.
APA
Stone, J. H., Spotswood, H., Unizony, S. H., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., Salvarani, C., Spiera, R., & Bao, M. (2022). New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology, 61(7), 2915–2922. https://doi.org/10.1093/rheumatology/keab780
Chicago
Stone, John H, Helen Spotswood, Sebastian H Unizony, Martin Aringer, Daniel Blockmans, Elisabeth Brouwer, Maria C Cid, et al. 2022. “New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from a Randomized Controlled Trial and Extension.” Rheumatology 61 (7): 2915–22. doi:10.1093/rheumatology/keab780.